A retrospective database study of insulin initiation in patients with Type 2 diabetes in UK primary care

Diabetic Medicine

Volumn 29, Issue 8, 2012, Pages

  Blak, B T ^a   Smith, H T ^b   Hards, M ^a   Maguire, A ^c   Gimeno, V ^d  

^a Cegedim Strategic Data Medical Research Ltd ^*  (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c UNITED BIOSOURCE CORPORATION   (United States)

^d H LUNDBECK A S   (Denmark)

Author keywords

Insulin treatment; Primary Care; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; BOLUS INJECTION; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; UNITED KINGDOM;

AGED; BODY MASS INDEX; BODY WEIGHT; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DRUG SUBSTITUTION; FAMILY PRACTICE; FEMALE; GREAT BRITAIN; HEALTH RESOURCES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; RETROSPECTIVE STUDIES;

EID: 84863999251     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03694.x     Document Type: Article

References (30)

1. International Diabetes Federation. Diabetes. The Policy Puzzle: Is Europe Making Progress?, 2nd edn. Brussels: International Diabetes Federation and Federation of European Nurses in Diabetes, 2008.
2. National Diabetes Audit. Executive Summary: Key Findings about the Quality of Care for People with Diabetes in England and Wales. Report for the Audit Period 2007-2008. Leeds: NHS Information Centre, 2008.
3. International Diabetes Federation. Diabetes Atlas. Prevalence estimates of diabetes mellitus (DM), 2030. Available at Last accessed 14 December 2010.
4. Williams R, Van Gaal L, Lucioni C; CODE-2 Advisory Board. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 2002; 45: S13-S17.
5. Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA. Mortality in people with type 2 diabetes in the UK. Diabet Med 2006; 23: 516-521.
6. Department of Health. Five Years on: Delivering the Diabetes National Service Framework. London: Department of Health, 2008.
7. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
8. National Institute for Health and Clinical Excellence (NICE). Type 2 Diabetes: Newer Agents for Blood Glucose Control in Type 2 Diabetes (NICE Short Clinical Guideline 87). London: NICE, 2009.
9. Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract 2007; 57: 455-460.
10. Jones S, Benroubi M, Castell C, Goday A, Lieble A, Timlin L et al. Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study. Curr Med Res Opin 2009; 25: 691-700.
11. National Institute for Health and Clinical Excellence (NICE). Management of Type 2 Diabetes - Managing Blood Glucose Levels. London: NICE, 2002.
12. National Institute for Health and Clinical Excellence (NICE). Type 2 Diabetes: the Management of Type 2 Diabetes (NICE Clinical Guideline 66). London: NICE, 2008.
13. Evans ML, Sharplin P, Owens DR, Chamberlain GH, Longman AJ, McEwan P. Insulin usage in type 2 diabetes mellitus patients in UK clinical practice: a retrospective cohort-based analysis using the THIN database. Br J Diabet Vasc Dis 2010; 10: 178-182.
14. Gordon J, Pockett RD, Tetlow AP, McEwan P, Home PD. A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study. Int J Clin Pract 2010; 64: 1609-1618.
15. Rubino A, McQuay LJ, Gough SC, Kvasz M, Tennis P. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK. Diabet Med 2007; 24: 1412-1418.
16. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007; 16: 393-401.
17. Blak BT, Thompson M. How does the health improvement network (THIN) data on prevalence of chronic diseases compared with national figures. Value Health 2009; 12(7): A253.
18. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Brindle P. The performance of the QRISK cardiovascular risk prediction algorithm in an external UK sample of patients from general practice: a validation sample. Heart 2008; 94: 34-39.
19. Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf 2008; 17: S250.
20. Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J Gen Intern Med 2007; 22: 453-458.
21. Scarlett JA, Gray RS, Griffin J, Olefsky JM, Kolterman OG. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care 1982; 5: 353-363.
22. Andrews WJ, Vasquez B, Nagulesparan M, Klimes I, Foley J, Unger R et al. Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 1984; 33: 634-642.
23. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985; 34: 222-234.
24. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care 1993; 16: 21-31.
25. Pratipanawatr T, Cusi K, Ngo P, Pratipanawatr W, Mandarino LJ, DeFronzo RA. Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes. Diabetes 2002; 51: 462-468.
26. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycemic agents in type 2 diabetes mellitus. Drug Saf 2007; 30: 1127-1142.
27. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26: 1902-1912.
28. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
29. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.
30. Glass LC, Qu Y, Lenox S, Kim D, Gates JR, Brodows R et al. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. Curr Med Res Opin 2008; 24: 639-644.